Clinical and economic aspects of the use of rituximab in non-Hodgkin's lymphoma
Braz. j. pharm. sci; 50 (3), 2014
Non-Hodgkin's lymphoma (NHL) consists of a group of neoplasias involving mainly B cells and represents 90% of all lymphomas. The current available therapy is based on chemotherapy associated with the monoclonal antibody rituximab (Mab Thera(r)), which targets the CD20 protein, present in over 80% of NHL ...